Johnson & Johnson (JNJ)

137.79
0.31 0.22
NYSE : Health Technology
Prev Close 138.10
Open 137.75
Day Low/High 137.48 / 138.39
52 Wk Low/High 118.62 / 148.99
Volume 1.08M
Avg Volume 7.77M
Exchange NYSE
Shares Outstanding 2.66B
Market Cap 368.63B
EPS 5.70
P/E Ratio 24.47
Div & Yield 3.60 (2.60%)

Latest News

Weekly Roundup

Strong earnings boost shares in a rebound week for stocks.

The Rally in Johnson & Johnson Looks Like it has Run Its Course

The Rally in Johnson & Johnson Looks Like it has Run Its Course

Let's check out the charts.

The Perils of Stock Investing: Cramer's 'Mad Money' Recap (Thursday 3/14/19)

The Perils of Stock Investing: Cramer's 'Mad Money' Recap (Thursday 3/14/19)

On the 14th anniversary for 'Mad Money', Jim Cramer talks about how to balance owning index funds and individual stocks.

Jim Cramer: 5 Examples Show Why Stock Investing Is So Difficult

Jim Cramer: 5 Examples Show Why Stock Investing Is So Difficult

Consider these five, right in front of you on this one day, so you get the perils of stock ownership and know how to handle them when they occur.

Video: Jim's Daily Rundown for Thursday

Jim discusses Johnson & Johnson, recent analyst notes on Apple, the cloud kings, and more!

Digging Down on the Dow 30

Digging Down on the Dow 30

Just 13 of the 30 Dow components are in clear uptrends.

Johnson & Johnson Hit With $29 Million Verdict in California Talc Suit

Johnson & Johnson Hit With $29 Million Verdict in California Talc Suit

Loss is latest setback for company's attempts to defuse thousands of claims against it alleging carcinogens in its signature baby powder caused cancer.

Jim Cramer: AAPL Should Get Into Diabetes Treatment and KHC Should Invest in Pot

Jim Cramer: AAPL Should Get Into Diabetes Treatment and KHC Should Invest in Pot

In this day and age, companies must be 'disruptors' or get left in the dust.

Home Depot and Johnson & Johnson Are Among Stocks Driving the S&P 500

Home Depot and Johnson & Johnson Are Among Stocks Driving the S&P 500

The bull market just had its 10-year anniversary but the gains have not been evenly distributed. A small number of stocks have been the main drivers, and some of these names are not what you might expect.

Jim Cramer: The Real Lesson of the 10-Year Bull Market Anniversary

Jim Cramer: The Real Lesson of the 10-Year Bull Market Anniversary

Did the Fed aid Microsoft? No, Microsoft aided Microsoft. J&J aided J&J. Procter aided Procter.

Weekly Roundup

With China reducing its GDP forecast and Europe's central bank growing cautious, markets turned lower this week.

The 6 Stocks To Watch: Cramer's 'Mad Money' Recap (Thursday 3/7/19)

The 6 Stocks To Watch: Cramer's 'Mad Money' Recap (Thursday 3/7/19)

Jim Cramer's watching six stocks to determine when the selling will end.

Could Kroger Lose the Grocery Wars Over This Challenge?

Allergan is another stock that could stay stuck in its Doldrums. See which of its peers Jim Cramer likes better and why.

Allergan Rises After FDA Accepts License Applications for Botox Supplements

Allergan Rises After FDA Accepts License Applications for Botox Supplements

Allergan wants Botox licenses for pediatric patients.

Jim Cramer: No Room for Cynicism, JNJ's New Depression Drug Is Lifesaving

Jim Cramer: No Room for Cynicism, JNJ's New Depression Drug Is Lifesaving

The approval of esketamine, known as Spravato, for use against severe depression is special -- it is saving lives.

Dow Ends Lower as Investors Eye Details From Trade Talks, Oil Prices Tumble

Dow Ends Lower as Investors Eye Details From Trade Talks, Oil Prices Tumble

The Dow Jones Industrial Average ended the day lower as details over the trade talks between the U.S. and China are awaited and oil prices tumble.

Johnson & Johnson's Spravato Approval by the FDA Is a Big Win

Sales of the drug for treatment-resistant depression might not be material this year, but should act as an additional driver to J&J's already above-market growing pharmaceutical franchise.

Jim Cramer on Why Johnson & Johnson's Anti-Depressant Is Important

Jim Cramer on Why Johnson & Johnson's Anti-Depressant Is Important

Johnson & Johnson received FDA approval for a nasal spray designed to treat patients with depression.

Video: Jim's Daily Rundown for Wednesday

Jim discusses the FDA approval of J&J's esketamine drug, the importance Disney's direct-to-consumer initiative, why you can't take your cue from a stock, and provides a view of Amgen.

Johnson & Johnson Edges Higher After FDA Approves Nasal Spray Antidepressant

Johnson & Johnson Edges Higher After FDA Approves Nasal Spray Antidepressant

Johnson & Johnson shares were rising Wednesday after the U.S. Food & Drug Administration approved a controversial antidespressant treatment, the first in three decades, even as it cautioned against potential misuse.

Jim Cramer Keeping an Eye on Dollar Tree, GE and Johnson & Johnson

Jim Cramer Keeping an Eye on Dollar Tree, GE and Johnson & Johnson

GE is getting slammed, Dollar Tree's earnings impressed investors, and Johnson & Johnson gets FDA approval for an anti-depressant. Here's what Jim Cramer thinks.

Jim Cramer: What to Watch from GE, Johnson & Johnson and Dollar Tree

Jim Cramer: What to Watch from GE, Johnson & Johnson and Dollar Tree

GE's getting hit in the markets, Johnson & Johnson gets a win from the FDA and Dollar Tree's weak forecast.

Johnson & Johnson, General Electric, NIO, Abercrombie - 5 Things You Must Know

Johnson & Johnson, General Electric, NIO, Abercrombie - 5 Things You Must Know

U.S. stock futures tilt lower as investors eagerly await new details on trade talks between the U.S. and China; Johnson & Johnson gets FDA approval for a nasal spray for patients with hard-to-treat depression; GE extends losses after CEO Larry Culp says he expects negative cash flow in 2019 for the company's industrial division.

Video: Jim's Daily Rundown for Tuesday

Jim breaks down the Salesforce.com action and explains why the digital transformation story still has significant legs to it. Then he compares the selling in CRM to what has happened in the past to several other names.

Let’s Explore the Reasons I Remain Sidelined

FAANG rallies are fine when breadth is playing along. FAANG rallies that suck the life out of other stocks (breadth) to feed themselves are bearish.

Weekly Roundup

Markets end volatile week little changed in spite of failed North Korea summit, and congressional testimony from Powell, Lighthizer and Cohen.

Video: Jim's Daily Rundown for Thursday

Jim discusses the positive Johnson & Johnson news related to asbestos not being found at its baby powder plants in India, yesterday's selloff in the MCOs, the market, trade with China after this morning's interview with Larry Kudlow, and more!

TheStreet Quant Rating: B+ (Buy)